The global cancer stem cells market size was valued at USD 679.5 million in 2016. The market is expected to expand at a CAGR of 9.98% during the forecast period. Currently, oncology therapeutics has entered a new era with conventional therapies such as radiotherapy, chemotherapy, & surgeries on one side and stem cell therapies on another side.
Over the past few years, stem cells are being successfully utilized in immuno-reconstitution and for replenishment of blood after tumor development or after tumor treatment. Furthermore, these cells have gained significant attention among healthcare entities for its employment as tools for delivery of anti-cancer agents as well as for tissue regeneration. A considerable number of entities have reported positive outcome of using this mode of tumor treatment.
While this therapy is receiving huge success in clinical oncology, a substantial number of published studies have mentioned cancer as “Cancer Stem Cell (CSC) disorder”. Due to introduction of this novel concept, an enormous potential for anti-CSCs therapeutics has been created.
This approach enables comprehensive investigation of essential as well as poorly understood clinical events in tumor initiation, propagation, relapse, and metastasis. This is considered as one of the major factors responsible for increasing interest in the cancer stem cell model.
There is accumulating evidence that sheds light on the existence of cancer stem cells and their role in conferring drug resistance. This further provides the possibility for generating novel targets to overcome therapeutic resistance by controlling regulation of these cells. Hence, CSCs, as potential therapeutic targets, enable therapeutic development that effectively combat tumor progression.
However, regulatory challenges pertaining to approval and usage of stem cell therapies are anticipated to inhibit growth of the market. In addition, certain manufacturing and pharmacological issues associated with this cell therapy development are estimated to slow down the progress of the market during the forecast period.
Understanding the biology of these cells and their role in management of tumor progression, the market can be segmented into two models of tumor treatment based on the mode of action. The first model incorporates targeted CSCs using monoclonal antibodies, recombinant proteins, nanomaterials, and other natural compounds. Majority of commercially available drugs facilitate tumor shrinkage, but do not target the root cause of tumor progression, which may further result in relapse of tumor growth.
This factor is providing a significant push to the growth of the segment. Increasing research on CSCs biology and their key signaling pathways, microenvironment, and surface markers are enabling development of agents that target these aspects of CSCs to control their regulation. Out of these aspects, agents targeting key pathways accounted for a major share.
Several review articles have documented roles of these pathways in functioning of CSCs. The second model deploys stem cells for tissue regeneration, immuno-reconstitution, and delivery of anti-cancer therapeutics. This segment is further bifurcated into autologous and allogenic cell treatment. Autologous treatments captured the largest market share in 2016 in terms of revenue.
Factors such as advantages of autologous transplant, affordability, improved survival rate of patients, and increase in transplantation procedures are poised to contribute to the growth of the segment. However, it has been observed that many cell therapy companies are increasingly focusing on the development of allogeneic cellular therapy products. This is expected to result in noteworthy growth of this segment over the forecast period.
The report has focused on the use of stem cells against a wide spectrum of tumor forms including breast, blood, lung, brain, colorectal, pancreas, and bladder, liver, head & neck, ovarian, prostate, and gastric tumor.
Out of all the tumor forms, breast cancer commanded the leading share of the overall revenue in 2016 owing to its rising incidence and the presence of a relatively large number of stem cell therapeutics for this tumor type. Moreover, the fact that autologous transplant has taken chemotherapy to a next level is likely to supplement the growth of the segment. Furthermore, stem cell therapies have been found to be successful in combating cardiotoxicity observed in survivors.
The lung cancer segment is projected to experience significant growth over the forecast period. The growth of the segment can be attributed to ongoing developments to curb the rising incidence of lung malignancy worldwide. In March 2016, a team of researchers at the Department of Cancer Biology, Mayo Clinic developed a combination therapy using auranofin, a rheumatoid arthritis drug, with an experimental targeted agent to hamper the growth of lung CSCs.
North America was the leading revenue contributor to the cancer stem cells market in 2016 due to the presence of a substantial number of organizations engaged in conducting R&D activities related to stem cell therapy. There are several internationally recognized hospitals and medical institutes, such as Cancer Treatment Centers of America at Midwestern Regional Medical Center, which offer stem cell transplant therapies.
Asia Pacific is expected to be a promising region in the arena owing to the presence of several organizations in the region that focus on R&D of stem cells. Moreover, funding agencies are providing grants to research communities to accelerate their scientific research on cancer stem cells in Asian countries.
Thermo Fisher Scientific, Inc.; AbbVie, Inc.; Merck KGaA; Bionomics; Lonza; Stemline Therapeutics, Inc.; Miltenyi Biotec; PromoCell GmbH; MacroGenics, Inc.; OncoMed Pharmaceuticals, Inc.; Irvine Scientific; STEMCELL Technologies Inc.; Sino Biological Inc.; and BIOTIME, INC are some of the key players operating in the market. In order to keep pace with the growing popularity of stem cell therapy in clinical oncology, these firms are undertaking various endeavors to stay competitive. Strategic alliances, facility expansion, and broadening product pipeline are some of the key initiatives undertaken by these participants.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, U.K., China, Japan, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global cancer stem cells market report on the basis of mode of action, cancer forms, and region:
Mode of Action Outlook (Revenue, USD Million, 2014 - 2025)
Targeted Cancerous Stem Cells (CSCs)
By Anti-CSC Therapeutics
WNT Signaling Pathway
Hedgehog Signaling Pathway
Notch Signaling Pathway
Immuno-evasion & Targeting Tumor Microenvironment
Stem Cell-based Cancer Therapy
Autologous SC Transplant
Allogeneic SC Transplant
Cancer Forms Outlook (Revenue, USD Million, 2014 - 2025)
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.